ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
PHAXIAM Therapeutics SA

PHAXIAM Therapeutics SA (PHXM)

3.10
0.00
(0.00%)
Closed July 13 4:00PM
0.00
0.00
(0.00%)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
3.10
Bid
2.72
Ask
3.30
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Market Cap
Previous Close
3.10
Open
-
Last Trade
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
-
Shares Outstanding
6,075,105
Dividend Yield
-
PE Ratio
-18.37
Earnings Per Share (EPS)
-3.87
Revenue
1.33M
Net Profit
-23.49M

About PHAXIAM Therapeutics SA

PHAXIAM Therapeutics SA, formerly known as ERYTECH PHARMA SA, is a France-based biopharmaceutical company developing medicinal products mainly in oncology, hematology and immunology fields of business. The company relies on the use of phages, natural bacteria-killing viruses. PHAXIAM Therapeutics SA... PHAXIAM Therapeutics SA, formerly known as ERYTECH PHARMA SA, is a France-based biopharmaceutical company developing medicinal products mainly in oncology, hematology and immunology fields of business. The company relies on the use of phages, natural bacteria-killing viruses. PHAXIAM Therapeutics SA is developing a portfolio of phages targeting three of the most resistant and dangerous bacteria, which alone account for more than two-thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. It offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells. The product is used for treatment of Acute Lymphoblastic Leukemia (ALL), a childhood cancer. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Lyon, Rhone, Fra
Founded
1970
PHAXIAM Therapeutics SA is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker PHXM. The last closing price for PHAXIAM Therapeutics was $3.10. Over the last year, PHAXIAM Therapeutics shares have traded in a share price range of $ 0.00 to $ 0.00.

PHAXIAM Therapeutics currently has 6,075,105 shares outstanding. The market capitalization of PHAXIAM Therapeutics is $18.83 million. PHAXIAM Therapeutics has a price to earnings ratio (PE ratio) of -18.37.

PHXM Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
VEVVicinity Motor Corporation
$ 0.7131
(122.15%)
116.26M
QLGNQualigen Therapeutics Inc
$ 0.428851
(108.89%)
420.2M
IVPInspire Veterinary Partners Inc
$ 10.52
(88.19%)
41.79M
TOYOTOYO Company Ltd
$ 2.699
(74.13%)
56.65M
NISNNiSun International Enterprise Development Group Company Ltd
$ 9.11
(51.33%)
7.4M
SISIShineco Inc
$ 0.8446
(-60.16%)
6.71M
MCACMonterey Capital Acquisition Corporation
$ 3.54
(-49.50%)
364.7k
MCACUMonterey Capital Acquisition Corporation
$ 7.64
(-28.40%)
2.61k
GENEGenetic Technologies Ltd
$ 0.80
(-27.93%)
780.46k
KZIAKazia Therapeutics Ltd
$ 0.8975
(-27.62%)
25.62M
QLGNQualigen Therapeutics Inc
$ 0.428851
(108.89%)
420.2M
MAXNMaxeon Solar Technologies Ltd
$ 0.237
(-1.54%)
286.13M
NVDANVIDIA Corporation
$ 129.24
(1.44%)
251.65M
AGRIAgriFORCE Growing Systems Ltd
$ 0.1001
(21.92%)
192.82M
LCIDLucid Group Inc
$ 4.25
(25.00%)
167.79M